Clinical Trials Sponsored by PDL BioPharma, Inc

Total 337 results

OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

Advanced Solid Tumor Malignancies

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Artax Biopharma Inc
Simbec Research

Completed

Potential Food Effect And Repeated Dosing of AX-024.HCl In Healthy Subjects

Healthy

United Kingdom
Duke University
PDI Healthcare Inc.

Completed

Measuring the Impact of an Enhanced Strategy for Daily Disinfection in Acute Care Hospital Rooms

Disinfection

United States
Avalyn Pharma Inc.
DevPro Biopharma

Recruiting

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

Progressive Pulmonary Fibrosis

United States
Immix Biopharma, Inc.
Novartis; BeiGene

Recruiting

Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors (IMMINENT-01)

Advanced Solid Tumor

Brazil
Immune Response BioPharma, Inc.
cro

Recruiting

A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Multiple Sclerosis | Secondary Progress Multiple Sclerosis

United States
Ultragenyx Pharmaceutical Inc
Mereo BioPharma

Active, not recruiting

Study to Assess Dose, Efficacy and Safety of Setrusumab in Participants With Osteogenesis Imperfecta (Orbit)

Osteogenesis Imperfecta

United States, Turkey, Germany, United Kingdom, Italy, Portugal, Canada, Australia, Argentina, France, Netherlands, Poland
BioFirst Corporation
ABVC BioPharma, Inc

Suspended

Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)

Retinal Detachment

Thailand, Australia
Ultragenyx Pharmaceutical Inc
Mereo BioPharma

Terminated

Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta

Osteogenesis Imperfecta

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer (ALPINE)

Stage IV Pancreatic Cancer

United States
doc.ai inc
UCB Biopharma SRL

Completed

Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares

Myasthenia Gravis

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors

Solid Tumors

United States
OncoMed Pharmaceuticals, Inc.

Terminated

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy (PINNACLE)

Stage IV Small Cell Lung Cancer

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies

Relapsed or Refractory Lymphoid Malignancies

United States
OncoMed Pharmaceuticals, Inc.

Completed

Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer

Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

Cancer Ovaries | Cancer Peritoneal | Cancer, Fallopian Tube

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10

Refractory Solid Tumors | Advanced Relapsed Tumors

United States
OncoMed Pharmaceuticals, Inc.

Completed

Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer

Liver Cancer | Hepatocellular Cancer

United States
OncoMed Pharmaceuticals, Inc.

Terminated

A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors

Metastatic Cancer | Locally Advanced Malignant Neoplasm

United States
OncoMed Pharmaceuticals, Inc.

Terminated

A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors

Metastatic Cancer | Locally Advanced Cancer

United States
Alios Biopharma Inc.
Janssen Pharmaceutica

Terminated

First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C

Chronic Hepatitits C

Georgia, Moldova, Republic of, France
CardioKine Inc.
Cardiokine Biopharma, LLC

Completed

Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure

Congestive Heart Failure

United States
Matinas BioPharma Nanotechnologies, Inc.
MB Clinical Research and Consulting LLC; Matinas Biopharma, Inc

Completed

Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia (ENHANCE-IT)

Hypertriglyceridemia

United States
Rion Inc.
ProPharma

Active, not recruiting

PEP on a Skin Graft Donor Site Wound

Skin Graft

United States
Pharmosa Biopharm Inc.
PPD

Completed

Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

Pulmonary Arterial Hypertension

United States
KGK Science Inc.
Boston Biopharm, Inc.

Completed

A Study to Compare the Pharmacokinetic Profile of a Proprietary Curcumin Forumulation to a Comparator Curcumin Product (15PCHB)

Healthy

Canada
Estrella Biopharma, Inc.
Eureka Therapeutics Inc.

Not yet recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (STARLIGHT-1)

Lymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
Seattle Children's Hospital
Umoja BioPharma, Inc.

Recruiting

A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma

Osteosarcoma

United States
Desitin Arzneimittel GmbH
BioPharma Services, Inc

Completed

Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting Conditions

Fasting

Canada
ARCA Biopharma, Inc.
Colorado Prevention Center

Completed

Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 (ASPEN)

Covid19

United States, Argentina, Brazil
Ultragenyx Pharmaceutical Inc
Novartis; Mereo BioPharma

Withdrawn

Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease

Chronic-kidney Disease Stage 5D on Stable Hemodialysis
Acrotech Biopharma Inc.
Axis Clinicals Limited

Completed

A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

Peripheral T-Cell Lymphoma (PTCL)

United States
Alios Biopharma Inc.
Vertex Pharmaceuticals Incorporated

Completed

First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

Moldova, Republic of, Romania, France
CardioKine Inc.
Biogen; Cardiokine Biopharma, LLC

Completed

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia

Hyponatremia With Normal Extracellular Fluid Volume

United States, Canada, Germany, India, Poland, Belgium
CardioKine Inc.
Biogen; Cardiokine Biopharma, LLC

Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

Euvolemic Hyponatremia

United States, Israel, India, Mexico, Peru, Belgium, Czech Republic, Italy
CardioKine Inc.
Biogen; Cardiokine Biopharma, LLC

Completed

International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430

Hyponatremia With Excess Extracellular Fluid Volume | Hyponatremia With Normal Extracellular Fluid Volume

United States
CardioKine Inc.
Biogen; Cardiokine Biopharma, LLC

Completed

A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study

Healthy

United States
Sarepta Therapeutics, Inc.
Hansa Biopharma AB

Active, not recruiting

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)

Duchenne Muscular Dystrophy

Spain
Desitin Arzneimittel GmbH
BioPharma Services, Inc

Completed

Bioavailability of Orfiril Long 500 mg Prolonged-Release Minitablets and Ergenyl Chrono 500 mg Prolonged-Release Tablets

Multiple Drug Use

Canada
Acerus Biopharma Inc.

Terminated

Evaluation of Testosterone Nasal Gel in Hypogonadal Boys

Hypogonadism

United Kingdom
Artax Biopharma Inc
Simbec-Orion Group

Completed

A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses

Autoimmune Diseases

United Kingdom
Acrotech Biopharma Inc.
Axis Clinicals Limited

Completed

Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials

Solid Tumor | Hematological Malignancies

United States
Acrotech Biopharma Inc.
Axis Clinicals Limited

Completed

Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

Solid Tumors | Hematological Malignancies

United States
Acrotech Biopharma Inc.
Axis Clinicals Limited

Terminated

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

Relapsed/Refractory Solid Tumors/Hematological Malignancies

United States
Alios Biopharma Inc.
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Chronic Hepatitis C

Moldova, Republic of
Alios Biopharma Inc.
Vertex Pharmaceuticals Incorporated

Terminated

First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

Australia, New Zealand
CardioKine Inc.
Biogen; Cardiokine Biopharma, LLC

Withdrawn

International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia

Hypervolemic Hyponatremia
Enteris BioPharma Inc.
Syneos Health; Parexel

Recruiting

Study to Evaluate the Pharmacodynamics and Efficacy of Leuprolide Tablets (Ovarest®) in Women With Endometriosis

Endometriosis

United States
Desitin Arzneimittel GmbH
BioPharma Services, Inc

Completed

Bioavailability and Food Effect of Sodium Valproate Minitablets in Healthy Subjects.

Food-drug Interaction

Canada

3

Subscribe